<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Rituximab versus azathioprine therapy in neuromyelitis optica spectrum disorder patients</title>
  </titleInfo>
  <titleInfo type="alternative">
    <title>عقار ريتوكسيماب مقابل عقار الأزاثيوبرين فى مرضى التهاب النخاع العصبى الطيفى البصرى</title>
  </titleInfo>
  <name type="personal">
    <namePart>Mohammed Said Hassan</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ahmed Nemr</namePart>
    <role>
      <roleTerm type="text">Supervisor</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Nevin Moheildin</namePart>
    <role>
      <roleTerm type="text">Supervisor</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sherif Hamdy</namePart>
    <role>
      <roleTerm type="text">Supervisor</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">theses</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">ua</placeTerm>
    </place>
    <place>
      <placeTerm type="text">Cairo</placeTerm>
    </place>
    <publisher>Mohammed Said Hassan</publisher>
    <dateIssued>2021</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
    <extent>164 P . :  charts ;  25cm</extent>
  </physicalDescription>
  <abstract>Background: Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system characterized by severe attacks of optic neuritis and longitudinally extensive transverse myelitis. Recently, the demonstration of a pathogenic role for the anti{u2013}aquaporin 4 (AQP4) antibody in NMO has marked a major advance in the understanding o the disease Aim of work: The aim of this study was to report the results of rituximab treatment in NMO spectrum disorders (NMOSDs) Patients and Methods: This was a retrospective observational study conducted on 74 Egyptian patients with NMOSDs. The patients{u2018} data were recruited from patient records in multiple sclerosis (MS) clinics, Neurology Departments, El- Maady Military Hospital (records from 2005) and Cairo University hospitals (Kasr Al-Ainy MS Clinic) (records from 2013) including their full medical history, general and neurological examination, MRI brain and spinal cord results, and laboratory investigation including: immune assays and AQP- 4antibody testing as per MS and MS mimics sheet of Kasr Al-Ainy MS clinic.Results: The study included 74 Patients with NMOSD according to criteria of Wagnerchuck 2015. Both sero-positive and sero-negative anti-aquaporin-4 (AQP-4) antibodies patients were included in the study. The patients were divided into three groups: group 1 (RTX group) included 25 patient; group 2 (AZA group) included 32 patients, and group 3 (Switchers) included 17 patients. Conclusion: our findings suggest that RTX is more effective and safe than AZA in NMO-SD patients. Further studies with larger sample sizes and longer duration of follow-up are reqired to confirm these findings in our country</abstract>
  <targetAudience authority="marctarget">specialized</targetAudience>
  <note type="statement of responsibility">Mohammed Said Hassan ; Supervised Sherif Hamdy , Nevin Moheildin , Ahmed Nemr</note>
  <note>Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Neuro Surgery</note>
  <note>Issued also as CD</note>
  <subject>
    <topic>Azathioprine </topic>
  </subject>
  <subject>
    <topic>Neuromyelitis </topic>
  </subject>
  <subject>
    <topic>Rituximab</topic>
  </subject>
  <identifier type="uri">http://172.23.153.220/th.pdf</identifier>
  <location>
    <url>http://172.23.153.220/th.pdf</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">EG-GiCUC</recordContentSource>
    <recordCreationDate encoding="marc">211104</recordCreationDate>
    <recordChangeDate encoding="iso8601">20250223032842.0</recordChangeDate>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
